It started with our scientific team developing a new approach to recombinant medicines. Our technology was different, less capital intensive, highly scalable and very cost-effective. Better, we believed.
And today rEVO Biologics is revolutionizing recombinant production through this approach. The use of rPRO Technology® enables the development of treatments that require large amounts of therapeutic proteins. With the initial market success of ATryn®, we are changing healthcare for the better by, for the first time, delivering a recombinant antithrombin replacement.
We intend to make safe, life-saving medicines available to the patients who need them most. Our vision is clear: to work diligently to help patients in need, because we recognize that every day makes a difference.
—Yann Echelard, Ph.D.
President and CEO, rEVO Biologics